Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer

Denise A Yardley1,2 1Sarah Cannon Research Institute, Nashville, TN, USA; 2Tennessee Oncology, Nashville, TN, USA Abstract: There is a high risk for bone loss and skeletal-related events, including bone metastases, in postmenopausal women with hormone receptor-positive breast cancer. Both the disea...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Yardley DA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	breast cancer bone metastases hormone receptor positive bone-related complications Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/269af8026fbc43f1ab786efcbd6a69cf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:269af8026fbc43f1ab786efcbd6a69cf
record_format	dspace
spelling	oai:doaj.org-article:269af8026fbc43f1ab786efcbd6a69cf2021-12-02T05:58:54ZPharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer1179-1314https://doaj.org/article/269af8026fbc43f1ab786efcbd6a69cf2016-05-01T00:00:00Zhttps://www.dovepress.com/pharmacologic-management-of-bone-related-complications-and-bone-metast-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Denise A Yardley1,2 1Sarah Cannon Research Institute, Nashville, TN, USA; 2Tennessee Oncology, Nashville, TN, USA Abstract: There is a high risk for bone loss and skeletal-related events, including bone metastases, in postmenopausal women with hormone receptor-positive breast cancer. Both the disease itself and its therapeutic treatments can negatively impact bone, resulting in decreases in bone mineral density and increases in bone loss. These negative effects on the bone can significantly impact morbidity and mortality. Effective management and minimization of bone-related complications in postmenopausal women with hormone receptor-positive breast cancer remain essential. This review discusses the current understanding of molecular and biological mechanisms involved in bone turnover and metastases, increased risk for bone-related complications from breast cancer and breast cancer therapy, and current and emerging treatment strategies for managing bone metastases and bone turnover in postmenopausal women with hormone receptor-positive breast cancer. Keywords: breast cancer, bone metastases, hormone receptor-positive, bone-related complications, interventions, management and management strategies, estrogen receptor-positiveYardley DADove Medical Pressarticlebreast cancerbone metastaseshormone receptor positivebone-related complicationsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol 2016, Iss Issue 1, Pp 73-82 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	breast cancer bone metastases hormone receptor positive bone-related complications Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	breast cancer bone metastases hormone receptor positive bone-related complications Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Yardley DA Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer
description	Denise A Yardley1,2 1Sarah Cannon Research Institute, Nashville, TN, USA; 2Tennessee Oncology, Nashville, TN, USA Abstract: There is a high risk for bone loss and skeletal-related events, including bone metastases, in postmenopausal women with hormone receptor-positive breast cancer. Both the disease itself and its therapeutic treatments can negatively impact bone, resulting in decreases in bone mineral density and increases in bone loss. These negative effects on the bone can significantly impact morbidity and mortality. Effective management and minimization of bone-related complications in postmenopausal women with hormone receptor-positive breast cancer remain essential. This review discusses the current understanding of molecular and biological mechanisms involved in bone turnover and metastases, increased risk for bone-related complications from breast cancer and breast cancer therapy, and current and emerging treatment strategies for managing bone metastases and bone turnover in postmenopausal women with hormone receptor-positive breast cancer. Keywords: breast cancer, bone metastases, hormone receptor-positive, bone-related complications, interventions, management and management strategies, estrogen receptor-positive
format	article
author	Yardley DA
author_facet	Yardley DA
author_sort	Yardley DA
title	Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer
title_short	Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer
title_full	Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer
title_fullStr	Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer
title_full_unstemmed	Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer
title_sort	pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/269af8026fbc43f1ab786efcbd6a69cf
work_keys_str_mv	AT yardleyda pharmacologicmanagementofbonerelatedcomplicationsandbonemetastasesinpostmenopausalwomenwithhormonereceptorpositivebreastcancer
_version_	1718400098909552640

Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer

Ejemplares similares